Syngene appoints Abhijit Zutshi as CCO
pharmafile | May 5, 2026 | Appointment | Research and Development | Syngene International
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the appointment of Abhijit Zutshi as Chief Commercial Officer (CCO).
Abhijit (Abhi) will be based in the US. As a member of the Executive Committee, he will lead Syngene’s commercial activities, including sales, client partnerships, marketing, brand building, digital initiatives and account management. He is tasked with further expanding the CRDMO’s pipeline of partners from innovative US-based biotechs and large pharma, as well as significantly deepening existing partnerships as more global customers undertake late-stage development and commercial supply with Syngene. The CRDMO continues to see growth in its US customer base and last year acquired its first manufacturing facility in Baltimore.
Abhi is a seasoned pharmaceutical executive with nearly 27 years of commercial experience across global markets. He spent 25 years at Biocon, most recently as CCO of the generics business, where he led both the drug substance and drug product divisions and built a global team focused on generic formulations. His career expertise spans sales, marketing, business development, portfolio management and market entry strategy across small and large molecules. Earlier in his career, he held a product specialist role at Pfizer, where he led the India launch of the Zosyn brand.
Peter Bains, Managing Director and CEO, Syngene International, said: “We are pleased to welcome Abhijit to Syngene’s leadership team. His depth of experience and strong track record…will be instrumental as we continue to evolve our service offerings and enhance our value proposition for clients worldwide. His appointment reinforces our commitment to building a world-class leadership team capable of driving our next phase of sustainable growth.”
